- Cyclopharm (CYC), set to receive a $3.1 million research and development tax incentive from AusIndustry for FY20
- Cyclopharm is the radiopharmaceutical company responsible for developing the Technegas product
- Technegas, a lung ventilation imaging agent, which also used to assess a patient’s lung function
- After receiving strong support from U.S. healthcare workers, the technology currently awaiting the tick of approval from the U.S. Food and Drug Administration
- Additionally, Cyclopharm recently raised $30 million through a placement to expand into the U.S. market
- Company shares have dropped 1.07 per cent and are trading at $2.78
